Amneal Pharmaceuticals (AMRX) Misses Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to Amneal Pharmaceuticals (AMRX) Misses Q4 EPS by 2c

Amneal Reports Fourth Quarter and Full Year 2021 Financial Results

March 2, 2022 6:00 AM EST

Q4 2021 Net Revenue of $537 million; GAAP Net Loss of $6 million; Diluted Loss per Share of $0.04
Q4 2021 Adjusted Net Income of $54 million (1), Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.18

Full Year Net Revenue of $2.1 billion; GAAP Net Income of $11 million; Diluted EPS of $0.07
Full Year 2021 Adjusted Net Income (1) of $258 million; Adjusted EBITDA (1) of $538 million; Adjusted Diluted EPS (1) of $0.85

Provides 2022 Financial Guidance of $2.15 to $2.25 billion in net revenue and $540 to $560 million in adjusted EBITDA

BRIDGEWATER, N.J.--(BUSINESS WIRE)--

... More